Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2%
Regulatory Neutral

GuideAI Health Corp. to Begin Trading on Cboe Canada Under the Symbol "GDAI"

AI-driven vascular disease detection moves to public markets, but execution and commercialization remain unproven.

By The Northwire Desk — AI Analysis Jun 29, 2026 · 08:00 GDAI NaN
Executive Summary
  • GuideAI Health Corp. has received final approval from Cboe Canada Inc. to list its common shares on the Cboe Canada exchange.
  • Trading under the ticker symbol "GDAI" is scheduled to commence at market open on June 29, 2026.
  • The company operates in healthcare technology, utilizing artificial intelligence to analyze routine CT scans for the early detection of peripheral vascular disease.
  • Management frames the listing as a milestone to scale the platform and expand access to diagnostic technology.
Material Impact
  • The announcement is a standard administrative and regulatory step for a company transitioning to or expanding its public market access.
  • No concurrent capital raise, valuation metrics, institutional anchor investors, or financial disclosures are included in the release.
  • Without details on share count, offering price, or immediate liquidity provisions, the listing itself does not alter the company's fundamental valuation or cash position.
  • The primary material impact is procedural: increased visibility, potential future access to public capital markets, and standard exchange compliance requirements.
GDAI · Price
Company Overview
  • GuideAI Health Corp. is a healthcare technology firm focused on artificial intelligence applications in medical imaging.
  • Core product: AI algorithms that analyze routine CT scans to identify peripheral vascular disease.
  • Target customers: Hospitals and radiology groups seeking earlier detection and more precise treatment planning.
  • Current stage: Pre-listing/pre-commercialization phase with no disclosed revenue or proven market penetration.
Read the original news release →

More from NaN

Jun 29, 2026 · 10:00

Cboe Canada Welcomes Listing of GuideAI Health Corp.

Regulatory